NCT00985790已完成2 期
Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine GSK2321138A in Healthy Children
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 599
- 试验地点
- 3
- 主要终点
- Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the 3 Fluarix Vaccine Strains.
研究概览
简要总结
The purpose of the present study is to assess the immunogenicity and safety of vaccine GSK2321138A in children.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Months 至 47 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For all subjects:
- •Subjects who the investigator believes that they and/or their Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.
- •Written informed consent obtained from the subject/from the LAR(s).
- •For unprimed subjects:
- •A male or female child aged 18 to 47 months at the time of the first vaccination.
- •Children who did not have influenza vaccine in a previous season.
- •For primed subjects from study NCT00764790:
- •Children who received Fluarix™ in the 111751 study NCT00764790.
排除标准
- •Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •History of hypersensitivity to any vaccine.
- •History of allergy or reactions likely to be exacerbated by any component of the vaccine.
- •Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before and ending 28 days after each dose of vaccine(s).
- •Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.
- •Acute disease at the time of enrolment.
- •History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
- •Receipt of another seasonal influenza vaccine outside of this study, during current (2009-2010) flu season.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccination Inhaled and topical steroids are allowed.
- •Administration of immunoglobulins and/or blood products within the 3 month preceding the first dose of study vaccine or planned administration during the study period.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
结局指标
主要结局
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the 3 Fluarix Vaccine Strains.
时间窗: At Day 0 [PRE] and at 28 days post last vaccination (Day 28 or Day 56) [POST]
Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 3 influenza strains assessed were the FLU A/Brisbane/59/07 (H1N1), Flu A/Uruguay/716/07 (H3N2) and Flu B/Brisbane/60/08 Victoria (VICT).The POST results were the primary outcome variables.
次要结局
- Number of Seroconverted Subjects Against 4 Strains of Influenza Disease.(At Days 28 and 56)
- Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.(At Days 28 and 56)
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms.(During the 7-day follow-up period (Days 0 to 6) after any vaccination)
- Number of Seroprotected Subjects Against 4 Strains of Influenza Disease.(At Days 0, 28 and 56)
- Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.(At Days 0, 28 and Day 56)
- Number of Seropositive Subjects Against 4 Strains of Influenza Disease.(At Days 0, 28 and 56)
- Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).(During the 28-day follow-up period (Days 0 to 27) after vaccination)
- Number of Subjects With Any and Related Serious Adverse Events (SAEs).(From Day 0 to Day 180 (study conclusion))
- Number of Subjects With Any Adverse Events of Specific Interest (AESIs).(From Day 0 to Day 180 (study conclusion))
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.(During the 7-day follow-up period (Days 0 to 6) after any vaccination)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeHaemophilus Influenzae Type bPoliomyelitisAcellular PertussisDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniDiphtheriaHepatitis BTetanusNCT00970307GlaxoSmithKline421
已完成
1 期
Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy ChildrenInfluenzaNCT01096056GlaxoSmithKline40
已完成
2 期
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseHaemophilus Influenzae Type bPoliomyelitisAcellular PertussisDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniHepatitis BDiphtheriaTetanusNCT01171989GlaxoSmithKline391
终止
2 期
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.PoliomyelitisNeisseria MeningitidisHaemophilus Influenzae Type bAcellular PertussisHepatitis BTetanusDiphtheriaNCT00871741GlaxoSmithKline16
已完成
3 期
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenRubellaMeaslesMumpsVaricellaNCT01506193GlaxoSmithKline716